[Announcement+] Jinwon Life Sciences Signs $1.65 Million Plasmid DNA Pharmaceutical Supply Contract

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 6th that it has signed a plasmid DNA pharmaceutical supply contract worth $1.65 million with a Korean bio company developing gene therapy drugs.

The contracting party has not been disclosed according to the contract, and the total contract amount is approximately 1.9 billion KRW when converted to Korean won.

GeneOne Life Science produces and supplies high-quality plasmid DNA pharmaceuticals through its subsidiary VGXI, a contract development and manufacturing organization (CDMO) facility compliant with current Good Manufacturing Practice (cGMP) standards.

Park Younggeun, CEO of GeneOne Life Science, stated, “As clinical development of gene therapy drugs is actively progressing worldwide, the demand for high-quality plasmid DNA pharmaceuticals is rapidly increasing, and customers trust VGXI’s production capacity, leading to continuous supply contract signings.”

GeneOne Life Science’s subsidiary VGXI has announced plans to build a new production facility and is currently expanding its existing production facilities.